New combo therapy aims to fight HPV head and neck cancer
NCT ID NCT07172256
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This phase 2 pilot study is testing a new drug called CUE-101, alone or combined with pembrolizumab, in 30 people with newly diagnosed, locally advanced HPV-16 head and neck cancer. The goal is to see if the combination boosts the immune system's ability to fight the cancer before standard treatment. Researchers will measure immune cell levels and monitor safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CUE-101 and pembrolizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with HPV-related head and neck cancer, potentially improving outcomes without the need for lifelong medication.
- What could go wrong
- This is a small, early-phase pilot study with only 30 participants, so results may not apply to everyone. The treatment may cause side effects or may not work better than existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?